42 results about "Combining vaccines" patented technology

The invention discloses a method for detecting the copy number of mRNA (messenger ribonucleic acid) of a novel crown RSV (respiratory syncytial virus) combined vaccine. A primer probe combination adopted by the detection method consists of primer pairs as shown in SEQ ID NO.2 and SEQ ID NO.3 and a probe as shown in SEQ ID NO.4, the 5'end of the probe is marked with a fluorescence reporter group, and the 3 'end of the probe is marked with a fluorescence quenching group. According to the detection method, correlation coefficients of equations between the Cq value and the template copy number are both larger than 0.99, amplification efficiency is both 90%-110%, and specificity and accuracy are good; the method can be used for quality control processes such as release detection in the combined vaccine development process and toxicological experiments, and has important significance and value for research and development and quality control of combined vaccines.

Provided are a primer-probe combination for real-time quantitative PCR, a related kit, and a method for using primers to measure the titers of measles, mumps and varicella virus pathogens. The method is applicable to clinical and laboratory detection, is fast and convenient, and has high sensitivity.

Provided is a liquid formulation of a six combined vaccine containing DPT-IPV-Hib-HBs, in which a HBs antigen is stably adsorbed and retained to an aluminum adjuvant, and PRP as a Hib antigen is stably coupled and retained to a carrier protein. A method for producing a stable liquid formulation of a six combined vaccine against diphtheria, pertussis, tetanus, polio, Haemophilus influenzae type b (Hib), and hepatitis B (HepB), the method comprising the following steps of: (1) mixing diphtheria toxoid (D) and tetanus toxoid (T) with an aluminum adjuvant to produce a DT adjuvant; (2) mixing a hepatitis B surface (HBs) antigen with the DT adjuvant obtained in step (1) to produce a DT-HBs adjuvant; (3) mixing a pertussis antigen (P) with the DT-HBs adjuvant obtained in step (2) to produce a DPT-HBs adjuvant; (4) mixing inactivated poliovirus (IPV) with the DPT-HBs adjuvant obtained in step (3) to produce a DPT-IPV-HBs adjuvant; (5) adding a succinate phosphate buffer to the DPT-IPV-HBs adjuvant obtained in step (4), and then adding PRP (PRP-T conjugate) as a Hib antigen to produce a mixture of DPT-IPV-Hib-HBs adjuvant and PRP-T conjugate; and (6) adjusting pH of the mixture of DPT-IPV-Hib-HBs adjuvant and PRP-T conjugate obtained in step (5) to 5.4 to 5.9.

The invention relates to the technical field of vaccine preparation, in particular to a porcine Japanese encephalitis virus and porcine parvovirus VP2 protein bivalent vaccine as well as a preparation method and application thereof. According to the invention, the JEV-PPV VP2 combined vaccine is prepared by combining the JEV whole-virus inactivated vaccine with the VLP assembled by the expressed PPV VP2 protein, so that the organism can be induced to generate good cellular immunity and humoral immunity, the organism is protected from being damaged by PPV and JEV, and a certain basis and direction are provided for research on the aspect of combined use of vaccines in the future.

The disclosure provides a hybrid protocol for identifying and quantitating viable Eimeria oocysts, such as in a mixed industrial scale vaccine sample. The hybrid protocol comprises the combination of a volumetric viability assessment, which allows for quantifying the number of viable oocysts, and a digital PCR (dPCR) assay, which allows for quantitative determination of the species composition of a mixed sample.

The invention discloses a mixed vaccine for preventing influenza and novel coronavirus infections. As a mixed vaccine for vaccination against influenza and novel coronavirus, a whole virus inactivated vaccine obtained by inactivating virus particles of influenza virus and novel coronavirus is used, whereby a neutralizing antibody against each virus is induced without affecting the effect of each vaccine. And a defense effect is obtained for attack of each virus. In addition, the mixed vaccine based on the combination shows a good neutralizing antibody induction and virus attack defense effect even if an adjuvant is not added.

The application discloses a novel group B meningococcal outer membrane protein bifunctional carrier, relates to the technical field of biopharmaceutical processes, and discloses a group B meningococcal outer membrane protein bifunctional carrier and application of the bifunctional carrier in a meningitis combined vaccine. The bifunctional carrier is human H factor binding protein fHbp, and comprises two kinds of recombinant proteins BA and BB, and the amino acid sequences of the two kinds of recombinin proteins are SEQ ID No. 62 and SEQ ID No. 63 respectively. The BA protein is coupled with group A capsule polysaccharide to form a group A combined vaccine, the BB protein is coupled with group C capsule polysaccharide to form a group C combined vaccine, and the two are mixed to form a group ABC triple vaccine. Each dose of the triple vaccine contains 40 μg of group A / C polysaccharide, 160 μg of BA / BB protein in total and 1.0 mg of aluminum adjuvant. The BA and BB proteins are expressed by E. coli, are broken by high-pressure homogenization, and are purified by anion exchange chromatography, and the purity is greater than or equal to 95%. The triple vaccine can simultaneously induce immune responses to groups A, B and C of meningitis, the serum bactericidal titer is greater than or equal to 1:32 after primary immunization, and the titer is maintained for more than 56 days after three immunizations.

The invention discloses a modular combined vaccine soluble microneedle patch based on a mechanical interlocking tenon-and-mortise structure as well as a preparation method and application of the modular combined vaccine soluble microneedle patch. According to the combined and spliced micro-needle vaccine patch designed by the invention, synchronous delivery of various vaccines is realized by virtue of a micro-needle technology through fragmented loading and mechanical interlocking'mortise and tenon 'structural design, mutual interference among different vaccines is reduced at the same time, efficient protection can be provided for groups needing multi-vaccine protection by virtue of one-time inoculation, the number of inoculants is reduced, and the immune procedure is simplified; vaccine hesitation is reduced, and inoculation rate is increased; meanwhile, the biosoluble material of the microneedle structure can quickly release antigens in the skin to stimulate immune cells to aggregate so as to enhance the immune effect; the micron-sized needle array (lt; 500 m) acts on the superficial layer of the skin, is painless and can be designed into a self-adhesive patch, so that the inoculation compliance is improved; single-dose inoculation can also reduce medical cost, is suitable for resource-deficient regions, improves accessibility and burdenability, and accelerates establishment of a population immune barrier.

Provided are a pneumococcal conjugate combined vaccine and a preparation method therefor. The combination comprises 26 different pneumococcal polysaccharide-protein conjugates, and the pneumococcal polysaccharide comprises a total of 26 serotypes, i.e., 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 24F, 33F and 35B. The carrier protein used by the conjugate is tetanus toxoid (TT). The polysaccharide is covalently linked to the TT by means of a cyano activation method so as to prepare a polysaccharide-protein conjugate stock solution, and the polysaccharide-protein conjugate stock solution is then adsorbed by an aluminum adjuvant in an appropriate proportion so as to obtain the pneumococcal conjugate vaccine. The pneumococcal polysaccharide used therein requires no degradation reaction, effectively protecting the antigenicity of the polysaccharide. Three consecutive batches of production of the conjugate stock solution and vaccine are performed, and the yield and each verification index of the conjugate are stable. The results of non-clinical safety evaluation research show that the vaccine has good safety and immunogenicity. The prepared pneumococcal conjugate vaccine is used for immunoprophylaxis of pneumococcal infection of relevant serotypes.

The application discloses a competitive ELISA detection method for Hib polysaccharide in an aluminum-containing adjuvant vaccine, and specifically, the method comprises the following steps: enzyme label plate preparation: coating Hib stock solution or PRP derivative on an enzyme label plate to prepare an enzyme label plate required for ELISA reaction; aluminum adsorption Hib sample treatment: blocking aluminum adjuvant adsorbed Hib reference and aluminum adjuvant containing vaccine samples with BSA, respectively, and then diluting the aluminum adjuvant adsorbed Hib reference and aluminum adjuvant combined vaccine samples after blocking; ELISA detection: adding the diluted aluminum adjuvant adsorbed Hib reference and aluminum adjuvant containing vaccine samples into the enzyme label plate, respectively, and then adding Hib specific antibody, generating ELISA signals through enzyme label antibody catalysis of substrates, establishing a mathematical relationship between absorbance and Hib polysaccharide content, and quantitatively calculating the Hib polysaccharide content in the aluminum adjuvant containing vaccine sample.

The invention relates to the field of biological medicine, and particularly discloses an RSV-influenza combined vaccine and application thereof. The RSV-influenza combined vaccine comprises a respiratory syncytial virus mRNA vaccine and an influenza vaccine, the respiratory syncytial virus mRNA vaccine also comprises lipid nanoparticles, and the mRNA is loaded in the lipid nanoparticles. The RSV-influenza combined vaccine is used for preventing infection of various respiratory viruses (RSV virus and influenza virus), and the LNP adjuvant of the RSV mRNA vaccine can greatly increase the immune response of the influenza vaccine and enhance the protection efficiency of the influenza vaccine in immunocompromised people.

The present invention relates to a combination of a first vaccine comprising a non-replicating immunogen of porcine erysipelothrix sp. And a non-replicating immunogen of porcine parvovirus and a second vaccine comprising a non-replicating immunogen of leptospira sp. And the first vaccine and the second vaccine are jointly injected into corium layers of a first injection part and a second injection part of the pig at different points to prophylactically treat the pig so as to resist swine erysipelothrix erysipelas infection, porcine parvovirus infection and leptospirosis infection.

Disclosed in the present invention is a compound adjuvant combined vaccine, comprising an immunogenic composition and a compound adjuvant. The immunogenic composition comprises a pertussis antigen, a diphtheria antigen and a tetanus antigen; and the compound adjuvant is composed of an aluminum adjuvant and a TLR9 receptor agonist. Further disclosed in the present invention is a use of the compound adjuvant in the preparation of the compound adjuvant combined vaccine for preventing pertussis, diphtheria and tetanus in a subject.

To provide combination vaccines for swine.SOLUTION: Provided is a combination vaccine for protection against a pathogenic infection with porcine circo virus type 2 (PCV2) and Mycoplasma hyopneumoniae (Mhyo) comprising non-replicating immunogen of PCV2 and non-replicating immunogen of Mhyo. The vaccine is characterized in that it is an oil-in-water emulsion comprising squalane, vitamin E-acetate and silica. In another embodiment, the invention provides a combination vaccine for protection against a pathogenic infection with PCV2 and Mhyo by intradermal administration.SELECTED DRAWING: None

The invention provides a combined vaccine based on Th1 / Th2 immune dynamic equilibrium as well as a preparation method and application of the combined vaccine. Subcutaneous delivery of interleukin 12 (IL12) and antigen (such as ovalbumin OVA) mRNA is adopted in the early stage of tumor occurrence, so that specific antigen recognition and T cell immune response of an organism are activated; when immune response enters a function decline stage, the tumor microenvironment is regulated through intratumor delivery of interleukin 4 (IL4) mRNA, the metabolic activity of T cells is maintained, and the depletion of the T cells is delayed. Through space (subcutaneous / intra-tumor) and time (early stage / middle stage) separated delivery of different immune factors, 'start-steady state maintenance 'type immune stylization regulation and control are realized, antigen-specific CTL reaction and persistent anti-tumor effect are remarkably enhanced, and the problem of immune bias caused by independent use of the antigen-specific CTL reaction and the persistent anti-tumor effect is solved.

The invention relates to the field of preparation of poultry vaccines, in particular to a preparation method of a chicken newcastle disease and avian influenza combined vaccine, which comprises the following steps: respectively inoculating susceptible chick embryos with Newcastle disease virus, infectious bronchitis virus and avian influenza virus, and harvesting infected chick embryo liquid to obtain first virus liquid, second virus liquid and third virus liquid; inoculating the susceptible duck embryo with the egg drop syndrome virus, and harvesting infected duck embryo liquid to obtain a fourth antigen; and concentrating the harvested first virus liquid, second virus liquid, third virus liquid and fourth antigen, inactivating, and mixing and emulsifying with an adjuvant. The vaccine prepared by the invention does not generate any adverse reaction to chickens, is high in experimental safety, can induce high-level neutralizing antibodies in immunized chickens, and can effectively reduce the incidence of Newcastle disease virus, infectious bronchitis virus, egg drop syndrome and avian influenza.

The application discloses an influenza virus universal and coronavirus combined polypeptide and application of a vaccine thereof, and belongs to the technical field of vaccine preparation. The vaccine is an artificial synthetic vaccine, has the characteristics of easy preparation, small toxicity, low cost, high titer, broad spectrum and conservation, and solves the complicated process of obtaining a vaccine by amplification transformation in the prior art, and improves the preparation efficiency and application efficiency. A combined polypeptide vaccine component having immunoprotection for multiple subtypes of influenza viruses and coronaviruses is designed for influenza viruses and novel coronaviruses, and Montanide ISA51 is used as an adjuvant. After mice immunized with the vaccine are infected with influenza viruses by nose dropping, it is shown that the vaccine immunization has a protective effect on mice adapted strains of influenza A H1N1 and H7N9 viruses, the combined vaccine composed of the screened six polypeptides has a protective effect on multiple influenza viruses, and has the potential to resist coronaviruses.

The invention provides an mRNA (messenger Ribonucleic Acid) molecule aiming at a coronavirus SARS-CoV-2 and / or an influenza virus, an mRNA vaccine containing the molecule and application of the mRNA vaccine. According to the combined vaccine, mRNA molecules respectively aim at Spike protein of an SARS-CoV-2 strain subjected to stable mutation or hemagglutinin protein of an influenza strain, optimized mRNA sequences can play an effective immune role, and the combined vaccine provided by the invention can activate specific immune response of an organism immune system aiming at various virus antigens; the immunoreaction can be synergistically enhanced through combined stimulation of various virus antigens.

The invention provides an application of a chicken-derived antiviral protein in a combined vaccine of H9N2 subtype avian influenza and Newcastle disease. An immunopotentiator is the chicken-derived antiviral protein IFITM1. According to the scheme, the chicken-derived antiviral protein IFITM1 serving as an immunopotentiator is matched with the H9N2 subtype avian influenza and Newcastle disease bivalent inactivated vaccine for immunization, immunized chickens can be induced to generate a higher-level H9N2 subtype avian influenza and Newcastle disease serum HI antibody, and the detoxification inhibition effect is improved. And 21 days after the antiviral protein IFITM1 is used as an immunopotentiator and is independently inoculated under the neck and subcutaneously, the detoxification of the chicken H9N2 subtype avian influenza virus and the Newcastle disease virus can be effectively inhibited, so that the chicken tissue injury condition is obviously reduced. At present, no poultry antiviral protein immunopotentiator inactivated vaccine appears on the market in China, and the poultry immunopotentiator provided by the scheme can more effectively prevent and control the avian influenza and the Newcastle disease by preparing the H9N2 subtype avian influenza and Newcastle disease bivalent inactivated vaccine, and can make up the vacancy of the current poultry market immunopotentiator at the same time.

The present invention discloses a combination vaccine for preventing hand, foot and mouth disease, comprising inactivated enterovirus 71 and inactivated coxsackievirus group A type 16. The present invention also discloses a method for preparing the combination vaccine, which exhibits excellent adsorption efficacy and stability. The multiple antigens described above do not interfere with each other's antigenicity or immune effects after immunization, resulting in excellent immunogenicity and safety. The use of the combination vaccine can significantly simplify the vaccination process, improve vaccination efficiency, and reduce costs.

The present invention discloses a combined immunization method of a porcine reproductive and respiratory syndrome (PRRS) inactivated vaccine and a live rabbit-derived classical swine fever (CSF) vaccine. 1) Prepare the PRRS inactivated vaccine; 2) Prepare a freeze-dried live rabbit-derived CSF vaccine containing anti-PRRSV specific splenic lymph node transfer factor at the nanoscale; 3) After warming the above two vaccines to room temperature, dissolve the live rabbit-derived CSF vaccine with the PRRS inactivated vaccine to obtain a mixed vaccine, and then immunize piglets with the mixed vaccine. The present invention uses a nanoscale live rabbit-derived CSF vaccine containing anti-PRRSV specific splenic lymph node transfer factor and a PRRS inactivated vaccine for combined immunization. After the nanoscale live rabbit-derived CSF vaccine enters the body, it can quickly and abundantly provide splenic lymph factors containing anti-PRRS in a short time, effectively stimulating the cellular immune response of the body and promoting the cellular immune response. The present invention can prevent two diseases with one injection, reduce the number of immunizations, reduce the immune stress of the pig herd, and improve the immunization effect.

The present invention discloses a novel coronavirus combined vaccine and its preparation method. The combined vaccine comprises the following antigenic components: a recombinant novel coronavirus RBD protein, hemagglutinin from an H1N1 influenza virus strain, hemagglutinin from an H3N2 influenza virus strain, hemagglutinin from a BY influenza virus strain, and hemagglutinin from a BV influenza virus strain. The novel coronavirus combined vaccine provided by the present invention has good compatibility of antigenic components, good immunogenicity, a low aluminum adjuvant content, low safety risks, is amenable to large-scale production, is highly compatible with viral mutations, and has promising application prospects.

The application relates to the technical field of bioengineering, and discloses a porcine epidemic diarrhea mRNA vaccine and a preparation method thereof, which comprises an mRNA sequence encoding the amino acid sequence of S protein of GIIa, GIIb and GIIc type porcine epidemic diarrhea virus with mutations, the mutated mRNA sequence has higher expression and better immunostimulatory effect, the expression is increased by 10 times, and excellent immunization effect is achieved in mice and piglets; the trivalent combined vaccine has broad-spectrum immunization effect and can reduce diarrhea of piglets, and the immunization effect is far superior to that of commercial vaccines tested in experiments. The mutated mRNA vaccine has outstanding progress and is suitable for popularization and application.

The invention provides a composite vaccine adjuvant based on ergothioneine-sulfhydrylated polypeptide and a vaccine composition and application thereof, and belongs to the crossing field of biotechnology and medicine (including veterinary use). The composite vaccine adjuvant comprises a component A and a component B, wherein the component A comprises the following components in percentage by weight: 0.5%-5.0% of L-ergothioneine, 0.3%-2.0% of (Gly-SH) n oligopeptide, 2.0%-8.0% of aluminum hydroxide and / or aluminum phosphate, 1.0%-3.0% of a targeting carrier, 5.5%-13.0% of a freeze-drying protective additive and the balance of a buffer solution; the component B is CpG ODN, and the final concentration of the component B is 10-25 mu g / mL. The composite vaccine adjuvant system integrates sulfhydrylation modification enhanced combination and multi-component synergistic immunization, can be used for inducing balanced Th1 / Th2 immune response of mammals (including human, pigs, cattle and the like) and birds (chicken, ducks and the like) to intracellular / extracellular pathogens, and can be adapted to subunit vaccines, inactivated vaccines, recombinant antigen vaccines and combined vaccines; meanwhile, healthy groups and immunosuppressive groups (young, stress substance and immunodeficient groups) are compatible.

The invention discloses a polypeptide combination vaccine as well as a preparation method and application thereof. The polypeptide combination vaccine comprises A02 and A24 polypeptides, a vaccine adjuvant cyclic diguanylate (CDGSF) and a linker L for coupling the polypeptides with the CDGSF. The polypeptide vaccine has good tumor inhibition activity.

The invention belongs to the technical field of biological medicine, and particularly relates to a mixed vaccine for expressing Brucella multiple antigens and a preparation method and application thereof, and the mixed vaccine is obtained by encapsulating active mRNA by lipid nanoparticles; the nucleotide sequence of the active mRNA is at least one of SEQ ID NO. 1 to SEQ ID NO. 8. The mixed vaccine is prepared by independently encapsulating mRNA (messenger Ribonucleic Acid) of eight key antigens of Brucella by using LNP (Lipoprotein Natriuretic Peptide). According to the mixed vaccine, the problem of antigen competition is avoided, the mixed vaccine can be efficiently delivered to an immune system, and each antigen can initiate balanced immune response.

The invention relates to the technical field of veterinary biological products, in particular to a preparation method of a mixed vaccine for combined immunization of foot-and-mouth disease and other pig live vaccines and an immunization method. The preparation method of the mixed vaccine for combined immunization of the foot-and-mouth disease and other pig live vaccines comprises the following steps: heating the foot-and-mouth disease inactivated vaccine to 20-25 DEG C, using the foot-and-mouth disease inactivated vaccine as a dilution matrix, dissolving the pig live vaccines needing combined immunization, and uniformly mixing to form a stable emulsion, thereby obtaining the mixed vaccine. According to the mixed vaccine disclosed by the invention, the immunological injection times are reduced, and the stress and cross infection risks of pigs are reduced; it is ensured that the titer of antibodies corresponding to all vaccines after combined immunization reaches the protection standard, and the immunization effect is better than that of independent immunization or simple mixed immunization; the method is simple to operate, low in cost and suitable for popularization and application in the aspect of enhancing immunity in large-scale pig farms.

The utility model discloses an efficient mixing and stirring device for detecting a vaccine adjuvant preparation, and belongs to the technical field of vaccine processing. The first stirring assembly, the second stirring assembly and the third stirring assembly are sequentially arranged on the stirring shaft, a vertical rod of the first stirring assembly is arranged on the side, close to the second stirring assembly, of the first stirring assembly, and the second stirring assembly and the stirring shaft form an inclined angle a in the rotating direction; the first transverse rods of the third stirring assemblies and the stirring shaft form inclination angles b, and the inclination angles b of the multiple third stirring assemblies are different. A plurality of groups of stirring assemblies are arranged on the stirring shaft of the stirring device, so that the mixed vaccine preparation adjuvant is fully stirred in a layered manner, and vertical rods are arranged on the stirring assemblies to form different angles, so that the mixed vaccine preparation adjuvant is circularly stirred from top to bottom; the situation that the uniformly stirred vaccine preparation adjuvant stands still in the mixing tank body and is separated, and then the stirring effect is influenced is avoided.

The invention belongs to the technical field of biological medicine, and provides an LNP-mRNA combined vaccine of respiratory syncytial virus and varicella-zoster virus and application of the LNP-mRNA combined vaccine, the combined vaccine comprises mRNA for coding RSVPre-F and mRNA for coding VZV gE-M which are mixed according to a certain proportion, and the mRNA is wrapped by lipid nanoparticles. The combined vaccine has immunogenicity and specificity aiming at the respiratory syncytial virus (RSV) and the varicella-zoster virus (VZV), and can effectively remove the viruses and play a comprehensive immune function. According to the invention, the blank in the field of RSV / VZV combined LNP-mRNA vaccines is filled up, and the clinical actual demand is powerfully met.

The invention belongs to the technical field of veterinary biological products, and particularly relates to a combined vaccine of a porcine deltacoronavirus antigen. The combined vaccine comprises an antigen and a pharmaceutically acceptable carrier, the antigen comprises an immune effective dose of porcine deltacoronavirus PDCoV HN02 or a culture thereof, the porcine deltacoronavirus PDCoV HN02 is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC NO: V202441, the preservation address is Wuhan University, Wuhan, China, and the preservation date is March 28, 2024. The invention also relates to an application of the porcine delta coronavirus PDCoV HN02 or the culture of the porcine delta coronavirus PDCoV HN02 in a combined vaccine. After pigs are immunized by the combined vaccine, clinical symptoms caused by mixed infection can be relieved, and effective protection is provided for the pigs.